Home » Newsletters » BioWorld Science

BioWorld Science

March 10, 1997

View Archived Issues

Pharmacia & Upjohn reports fourth-quarter and full-year sales and earnings

Sepracor announces 1996 financial results

Vanguard Medica preliminary results for the year ended December 31, 1996

Vasogen reports fiscal 1996 results

Antitumor agents disclosed by University of Vermont

HBV mutants for diagnosis and therapy described by Abbott

Procyte discloses zinc(II) complexes especially effective against HIV

Agents for CNS disorders described by American Home Products

Pharmacia & Upjohn discloses aromatase inhibitors

New antifungal agents from Lilly

MMP inhibitors from Ono

Merck KGaA discloses ET antagonists

AY-4166: preclinical toxicity and pharmacokinetics studies

Preclinical toxicity, pharmacokinetics and metabolism of SM-9018 described

New PDE III/IV inhibitor described

Potent, long-acting ETA antagonist described by Zeneca

New selective alpha1a/A-antagonist from Abbott

ImaRx reports discoveries related to gene expression enhancement

AltaRex receives funding for clinical trials on Ovarex

Synsorb sponsors research on carbohydrate synthesis

Axcan signs distribution agreements for Protectaid

Emisphere's carriers for oral delivery of proteins covered by patent

Spiros products progressing through pipeline

Patient enrollment in phase I study of HIV/ACT complete

Pharmacia & Upjohn purchases U.S. manufacturing rights for Cygnus' Nicotrol

Fluticasone + loratadine for seasonal allergic rhinitis

Millennium obesity gene patent application receives U.S. notice of allowance

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...